Cediranib: Profile of a novel anti-angiogenic agent in patients with glioblastoma

Jörg Dietrich, Daphne Wang, Tracy T. Batchelor

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Background: Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas. Objective: This review evaluates the preclinical and clinical data for cediranib (AZD2171), a potent oral inhibitor of the VEGF receptor tyrosine kinase. Methods: We summarize both preclinical and clinical data for cediranib, with a focus on the treatment of glioblastomas. Results/conclusion: Cediranib is an effective drug in patients with glioblastoma, acting through inhibition of angiogenesis and normalization of tumor vasculature. Reduction of vasogenic brain edema is a key component of its treatment effect in this patient population. The primary side effects of cediranib include fatigue, diarrhea and hypertension.

Original languageEnglish
Pages (from-to)1549-1557
Number of pages9
JournalExpert Opinion on Investigational Drugs
Issue number10
StatePublished - Oct 2009


  • AZD2171
  • Adverse effects
  • Angiogenesis
  • Brain tumors
  • Cediranib
  • Cerebral edema
  • Glioblastoma
  • Invasion
  • Malignant glioma
  • Stem cells


Dive into the research topics of 'Cediranib: Profile of a novel anti-angiogenic agent in patients with glioblastoma'. Together they form a unique fingerprint.

Cite this